Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant-Reference-Cited by-同舟云学术

Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant

Published:2014-01-28 Issue:8 Volume:55 Page:1922-1924
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

von Tresckow Bastian,Müller Horst,Eichenauer Dennis A.,Glossmann Jan P.,Josting Andreas,Böll Boris,Klimm Beate,Sasse Stephanie,Fuchs Michael,Borchmann Peter,Engert Andreas

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.854888

Reference17 articles.

1. Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

2. Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

3. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

4. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

5. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era;Seminars in Hematology;2024-06

2. Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma;Blood Advances;2023-11-02

3. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study;Blood Advances;2023-10-13

4. Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy;Cancers;2023-09-11

5. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents;Blood;2023-03-01